We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study
Read MoreHide Full Article
Kodiak Sciences Inc. (KOD - Free Report) announced that it has completed enrollment in the pivotal phase IIb/III DAZZLE study, which is evaluating its lead pipeline candidate KSI-301 for the treatment of patients with neovascular wet age-related macular degeneration (wet AMD).
The randomized DAZZLE study evaluated the efficacy, durability and safety of KSI-301 in the given patient population and enrolled more than 550 patients worldwide, surpassing the enrollment target. The study has a one-year primary efficacy endpoint and the top-line data from the same is expected in early 2022.
Shares of Kodiak Sciences have rallied 57.9% so far this year compared with the industry’s increase of 0.5%.
We note that KSI-301, an investigational anti-VEGF therapy built on Kodiak Sciences' proprietary antibody biopolymer conjugate (ABC) platform, is being developed for treating various neovascular retinal vascular diseases.
In the third quarter of 2020, Kodiak Sciences treated the first patient in the two pivotal phase III studies of GLEAM and GLIMMER, which is investigating KSI-301 for treating diabetic macular edema (DME). Another phase III BEACON study is evaluating KSI-301 for addressing macular edema due to retinal vein occlusion (RVO).
These studies along with the DAZZLE pivotal study are likely to form the basis of the biologics license applications (BLA) for KSI-301 to support its potential approval and commercialization.
Kodiak Sciences remains on course to file a single BLA for KSI-301 in 2022 to treat wet AMD, DME and RVO.
Further, the company plans to initiate an additional phase III GLOW study in early 2021 to investigate KSI-301 for treating patients with non-proliferative diabetic retinopathy without DME.
Zacks Rank & Stocks to Consider
Kodiak Sciences currently carries a Zacks Rank #4 (Sell).
Abeona Therapeutics’ loss per share estimates have narrowed 9.3% for 2020 and 9.8% for 2021 over the past 60 days.
Halozyme’s earnings estimates have been revised 19.7% and 16.6% upward for 2020 and 2021 each over the past 60 days. The stock has rallied 119.1% year to date.
Cara Therapeutics’ loss per share estimates have narrowed 14.2% for 2020 and 22.5% for 2021 over the past 60 days.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study
Kodiak Sciences Inc. (KOD - Free Report) announced that it has completed enrollment in the pivotal phase IIb/III DAZZLE study, which is evaluating its lead pipeline candidate KSI-301 for the treatment of patients with neovascular wet age-related macular degeneration (wet AMD).
The randomized DAZZLE study evaluated the efficacy, durability and safety of KSI-301 in the given patient population and enrolled more than 550 patients worldwide, surpassing the enrollment target. The study has a one-year primary efficacy endpoint and the top-line data from the same is expected in early 2022.
Shares of Kodiak Sciences have rallied 57.9% so far this year compared with the industry’s increase of 0.5%.
We note that KSI-301, an investigational anti-VEGF therapy built on Kodiak Sciences' proprietary antibody biopolymer conjugate (ABC) platform, is being developed for treating various neovascular retinal vascular diseases.
In the third quarter of 2020, Kodiak Sciences treated the first patient in the two pivotal phase III studies of GLEAM and GLIMMER, which is investigating KSI-301 for treating diabetic macular edema (DME). Another phase III BEACON study is evaluating KSI-301 for addressing macular edema due to retinal vein occlusion (RVO).
These studies along with the DAZZLE pivotal study are likely to form the basis of the biologics license applications (BLA) for KSI-301 to support its potential approval and commercialization.
Kodiak Sciences remains on course to file a single BLA for KSI-301 in 2022 to treat wet AMD, DME and RVO.
Further, the company plans to initiate an additional phase III GLOW study in early 2021 to investigate KSI-301 for treating patients with non-proliferative diabetic retinopathy without DME.
Zacks Rank & Stocks to Consider
Kodiak Sciences currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the biotech sector include Abeona Therapeutics Inc. , Halozyme Therapeutics, Inc. (HALO - Free Report) and Cara Therapeutics, Inc. (CARA - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abeona Therapeutics’ loss per share estimates have narrowed 9.3% for 2020 and 9.8% for 2021 over the past 60 days.
Halozyme’s earnings estimates have been revised 19.7% and 16.6% upward for 2020 and 2021 each over the past 60 days. The stock has rallied 119.1% year to date.
Cara Therapeutics’ loss per share estimates have narrowed 14.2% for 2020 and 22.5% for 2021 over the past 60 days.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>